Foerch C, Montaner J, Furie K L, Ning M M, Lo E H
Neuroprotection Research Laboratory, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Neurology. 2009 Aug 4;73(5):393-9. doi: 10.1212/WNL.0b013e3181b05ef9.
Emerging data suggest that a wide array of measurable biomarkers in blood may provide a novel window into the pathophysiology of stroke. In this review, we survey the state of progress in the field. Three specific questions are assessed. Can biomarkers augment the clinical examination and powerful brain imaging tools to enhance the accuracy of the diagnostic process? Can biomarkers be used to help triage patients for thrombolytic therapy? Can biomarkers help predict patients who are most susceptible to malignant infarction? Many encouraging molecular candidates have been found that appear to match the known cascades of neurovascular injury after stroke. However, whether these putative biomarkers may indeed have direct clinical utility remains to be quantitatively validated. Larger clinical trials are warranted to establish the sensitivity and specificity of biomarkers for routine use in clinical stroke.
新出现的数据表明，血液中一系列可测量的生物标志物可能为中风的病理生理学提供一个新窗口。在本综述中，我们考察了该领域的进展状况。评估了三个具体问题。生物标志物能否增强临床检查和强大的脑成像工具，以提高诊断过程的准确性？生物标志物能否用于帮助对患者进行溶栓治疗的分类？生物标志物能否帮助预测最易发生恶性梗死的患者？已经发现了许多令人鼓舞的分子候选物，它们似乎与中风后已知的神经血管损伤级联反应相匹配。然而，这些假定的生物标志物是否确实具有直接的临床效用仍有待定量验证。需要进行更大规模的临床试验，以确定生物标志物在临床中风常规应用中的敏感性和特异性。
